Concepedia

Friedhelm Helling

FH

Statistics

Publications

15

Citations

1.7K

H-Index

15

Active since

1990

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Philipps University of Marburg

Max Planck Institute for Medical Research

University of Bonn

Friedhelm Helling is an author at Memorial Sloan Kettering Cancer Center specializing in life sciences, oncology, and immunology.

Publications per year

1990–2009

15

Publications

15

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

Philip O. Livingston, Gabriel Wong, Sucharita Adluri et al. · Journal of Clinical Oncology · 1994 · 520 citations

, , +17

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

Philip O. Livingston, Sucharita Adluri, Friedhelm Helling et al. · Vaccine · 1994 · 214 citations

, , +16

GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

Friedhelm Helling, Shengle Zhang, A Shang et al. · PubMed · 1995 · 207 citations

, , +17

GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.

Friedhelm Helling, A Shang, M J Calves et al. · PubMed · 1994 · 179 citations

, , +17

Ganglioside expression on human malignant melanoma assessed by quantitative immune thin‐layer chromatography

Wm. Bradley Hamilton, Friedhelm Helling, Kenneth O. Lloyd et al. · International Journal of Cancer · 1993 · 156 citations

, , +9

1–5 of 15